{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:24:40Z","timestamp":1788578680863,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.regg.2026.101748","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:37:17Z","timestamp":1771454237000},"page":"101748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Manejo multidisciplinar del paciente mayor con c\u00e1ncer de pr\u00f3stata avanzado"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-2590","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Molina-Garrido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-7207","authenticated-orcid":false,"given":"Raquel","family":"Ram\u00edrez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"S\u00e1nchez Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cruz Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5497-1457","authenticated-orcid":false,"given":"Mar\u00eda","family":"S\u00e1nchez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"R\u00edos Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"de Cabo Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mart\u00edn Ord\u00f3\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2669-1386","authenticated-orcid":false,"given":"\u00c1ngel","family":"Acosta Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cassinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.regg.2026.101748_bib0305","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica. Las cifras del c\u00e1ncer en Espa\u00f1a. Madrid: SEOM; 2024 [consultado 23 Jul 2025]. Disponible en: https:\/\/www.seom.org\/images\/LAS_CIFRAS_2024.pdf"},{"key":"10.1016\/j.regg.2026.101748_bib0310","unstructured":"National Cancer Institute: Surveillance, Epidemiology and End Result Program. Cancer Stat Fact: Prostate cancer [consultado 23 Jul 2025]. Disponible en: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"10.1016\/j.regg.2026.101748_bib0315","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/cncr.26392","article-title":"Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality","volume":"188","author":"Scosyrev","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/13685538.2016.1277516","article-title":"Use of geriatric asessment and screening tools of frailty in elderly patients with prostate cancer. Review","volume":"20","author":"Molina-Garrido","year":"2017","journal-title":"Aging Male."},{"key":"10.1016\/j.regg.2026.101748_bib0325","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0330","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of prostate cancer in elderly patients: Recommendations of a task force of the International Society of Geriatric Oncology","volume":"72","author":"Droz","year":"2017","journal-title":"Eur Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0335","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0340","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41416-023-02492-8","article-title":"Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from phase 3 randomised clinical studies TITAN and SPARTAN","volume":"130","author":"Shen","year":"2024","journal-title":"Br J Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0345","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.euo.2023.11.012","article-title":"Clinical outcomes of enzalutamide in metastatic hormone-sensitive prostate cancer in patients aged <75 and \u226575 years: ARCHES post hoc analysis","volume":"7","author":"Gomez-Veiga","year":"2024","journal-title":"Eur Urol Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.regg.2026.101748_bib0350","doi-asserted-by":"crossref","first-page":"S968","DOI":"10.1016\/j.annonc.2023.09.2742","article-title":"1792P Effects of enzalutamide on overall survival +\/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)","volume":"34","author":"Horvath","year":"2023","journal-title":"Ann Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0355","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase iii ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0360","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: Treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0365","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.regg.2026.101748_bib0370","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: Data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08 CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0375","doi-asserted-by":"crossref","first-page":"e806","DOI":"10.1016\/j.clgc.2019.05.001","article-title":"Is there a benefit of addition docetaxel, abiraterone celecoxib, or zoledronic acid in initial treatments for patients older than 70 years with hormone-sensitive advanced prostate cancer? A meta-analysis","volume":"17","author":"Landre","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0380","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.regg.2026.101748_bib0385","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0390","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase iii E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0395","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clgc.2021.03.016","article-title":"Efficacy and adverse events of docetaxel for metastatic hormone-sensitive prostate cancer among elderly men: A post hoc analysis of the CHAARTED trial","volume":"19","author":"Li","year":"2021","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0400","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0405","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase iii ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0410","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet."},{"issue":"6_suppl","key":"10.1016\/j.regg.2026.101748_bib0415","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2023.41.6_suppl.20","article-title":"Efficacy and safety of abiraterone acetate plus prednisone and ADT +\/- docetaxel in older patients (\u226570 years), with de novo mCSPC, compared to younger patients (70 Years): The PEACE-1 trial","volume":"41","author":"Mourey","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0420","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.regg.2026.101748_bib0425","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0430","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2013.09.005","article-title":"Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy","volume":"65","author":"Mulders","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0435","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdt571","article-title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase iii AFFIRM trial","volume":"25","author":"Sternberg","year":"2014","journal-title":"Ann Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0440","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.juro.2015.07.004","article-title":"Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy na\u00efve patients with metastatic castration resistant prostate cancer","volume":"194","author":"Smith","year":"2015","journal-title":"J Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0445","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-019-5280-6","article-title":"Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study","volume":"19","author":"Boegemann","year":"2019","journal-title":"BMC Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0450","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: Results from PREVAIL","volume":"27","author":"Graff","year":"2016","journal-title":"Ann Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0455","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgo.2013.12.001","article-title":"Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial","volume":"5","author":"Horgan","year":"2014","journal-title":"J Geriatr Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0460","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/j.clgc.2016.03.018","article-title":"Predictors of chemotherapy-induced toxicity and treatment outcomes in elderly versus younger patients with metastatic castration-resistant prostate cancer","volume":"14","author":"Kongsted","year":"2016","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0465","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetxel treatment: A randomized open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.regg.2026.101748_bib0470","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","article-title":"E Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme","volume":"50","author":"Heidenreich","year":"2014","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.regg.2026.101748_bib0475","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jgo.2020.02.014","article-title":"Cabazitaxel in patients aged \u226580 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan","volume":"11","author":"Matsubara","year":"2020","journal-title":"J Geriatr Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0480","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12032-019-1304-y","article-title":"Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs","volume":"36","author":"Calvani","year":"2019","journal-title":"Med Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0485","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1532-5415.2010.02833.x","article-title":"Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer","volume":"58","author":"Fontana","year":"2010","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.regg.2026.101748_bib0490","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.prnil.2015.12.003","article-title":"Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A \u201creal world\u201d experience","volume":"4","author":"Tralongo","year":"2016","journal-title":"Prostate Int."},{"key":"10.1016\/j.regg.2026.101748_bib0495","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0500","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.regg.2026.101748_bib0505","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.regg.2026.101748_bib0510","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.regg.2026.101748_bib0515","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Ckarke","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.regg.2026.101748_bib0520","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase iii MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0525","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.regg.2026.101748_bib0530","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.23.02182","article-title":"US Food and Drug administration approval summary: Talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Heiss","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0535","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.3390\/curroncol28050318","article-title":"Clinical outcomes from dose-reduced radiotherapy to the prostate in elderly patients with localized prostate cancer","volume":"28","author":"Samson","year":"2021","journal-title":"Curr Oncol."},{"key":"10.1016\/j.regg.2026.101748_bib0540","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0545","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.regg.2026.101748_bib0550","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.regg.2026.101748_bib0555","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.regg.2026.101748_bib0560","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.prnil.2018.08.001","article-title":"Hematologic toxicity of radium-223 in erderly patients with metastatic castration resistant prostate cancer: A real-life experience","volume":"7","author":"Costa","year":"2019","journal-title":"Prostate Int."},{"key":"10.1016\/j.regg.2026.101748_bib0565","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.122.265259","article-title":"Safety and efficacy of [177Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer: Report on 80 patients over the age of 80 years","volume":"64","author":"Tauber","year":"2023","journal-title":"J Nucl Med."},{"key":"10.1016\/j.regg.2026.101748_bib0570","series-title":"Fundamentos de oncogeriatr\u00eda. Tratado de oncolog\u00eda m\u00e9dica en el paciente anciano","first-page":"365","article-title":"Comorbilidad en el paciente anciano y en el paciente anciano con c\u00e1ncer","author":"Huedo R\u00f3denas","year":"2019"},{"key":"10.1016\/j.regg.2026.101748_bib0575","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1200\/EDBK_237641","article-title":"A practical guide to geriatric syndromes in older adults with cancer: A focus on falls, cognition, polypharmacy, and depression","volume":"39","author":"Magnuson","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"10.1016\/j.regg.2026.101748_bib0580","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/gerona\/glp180","article-title":"Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer","volume":"65","author":"Koroukian","year":"2010","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"10.1016\/j.regg.2026.101748_bib0585","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead073","article-title":"Association between heart failure and the incidence of cancer: A systematic review and meta-analysis","volume":"3","author":"Jaiswal","year":"2023","journal-title":"Eur Heart J Open."},{"key":"10.1016\/j.regg.2026.101748_bib0590","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25826","article-title":"Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: A systematic review and meta-analysis","volume":"3","author":"Myint","year":"2020","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.regg.2026.101748_bib0595","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cts.13451","article-title":"Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta-analysis","volume":"16","author":"Huang","year":"2023","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.regg.2026.101748_bib0600","unstructured":"Gu\u00eda de buena pr\u00e1ctica cl\u00ednica en geriatr\u00eda. C\u00e1ncer de pr\u00f3stata avanzado. Madrid: Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda; 2024. ISBN: 978-84-09-62736-3 [consultado 24 Nov 2025]. Disponible en: https:\/\/www.segg.es\/media\/descargas\/Guia-SEGG-Cancer-de-Prostata-Avanzado.pdf"}],"container-title":["Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211139X26000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211139X26000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:48:19Z","timestamp":1772549299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211139X26000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0211139X26000077"],"URL":"https:\/\/doi.org\/10.1016\/j.regg.2026.101748","relation":{},"ISSN":["0211-139X"],"issn-type":[{"value":"0211-139X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manejo multidisciplinar del paciente mayor con c\u00e1ncer de pr\u00f3stata avanzado","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.regg.2026.101748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SEGG. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101748"}}